|
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2024 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape |
Mar 2024 |
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria |
Mar 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
Mar 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation |
Mar 2024 |
Haematologica |
Aplastic Anemia |
|
Progress in medical therapy in aplastic anemia: why it took so long? |
Feb 2024 |
International Journal of Hematology |
Aplastic Anemia |
|
Aplastic anemia: history and recent developments in diagnosis and treatment |
Feb 2024 |
International Journal of Hematology |
Aplastic Anemia |
|
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
Jan 2024 |
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial |
Jan 2024 |
Lancet |
Myelodysplastic Syndromes (MDS) |
